ClinicalTrials.gg
RecruitingNCT05255653RAINBO-GREENUpdated Oct 8, 2026

Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features

A Phase 3 interventional study of Pelvic external beam radiotherapy and Chemotherapy in Endometrial Cancer, sponsored by Leiden University Medical Center. Recruiting at 60 sites in 7 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Leiden University Medical Center · Phase 3, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Nov 2021; still recruiting 5 years later.
Updated Oct 8, 2026First sites in 4 new countriesNo longer in United Kingdom+9 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
316
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 128 studies in Endometrial Neoplasms with a site in Canada — 37 open to participants now, 59 under way, 17 of them phase 3. Endometrial Neoplasms · Canada.

Planned enrollment
34th of 110
316 · median 154
Started
2021
with 10 others
Phase 3
28 of 128
8 open now
Primary completion
2030-01
later than 52 of 58 live
Registered
89th of 128
by date

Among the 128 studies in Endometrial Neoplasms with a site in Canada, this one is the 34th largest by planned enrollment of the 110 interventional ones that give a count, is one of 11 that started in 2021, is one of 28 in phase 3, reaches primary completion later than 52 of the 58 other live ones, and was the 89th registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

37 of the 128 studies in Endometrial Neoplasms with a site in Canada are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 128 studies in Endometrial Neoplasms with a site in Canada, or all of them as a file.
02

Study summary

RAINBO MMRd-GREEN is an international, multicenter, phase III randomised trial wherein adjuvant pelvic external beam radiotherapy combined with and followed by durvalumab for one year is compared to adjuvant pelvic external beam radiotherapy with or without chemotherapy.

Read the detailed description

The MMRd-GREEN trial (NCT05255653) is an international, multicenter, phase III randomised trial wherein adjuvant pelvic external beam radiotherapy combined with and followed by durvalumab for one year is compared to adjuvant pelvic external beam radiotherapy with or without chemotherapy.

There are three other RAINBO trials, which are registered separately:

The p53abn-RED trial (NCT06712472) is an international, multicenter, phase III randomised trial wherein patients with completely resected invasive stage I-III p5abn endometrial cancer and treated with adjuvant chemoradiation will be randomized between olaparib for one year and observation.

The NSMP-ORANGE trial (NCT07831902) is an international, multicenter, non-inferiority phase III randomised trial wherein patients with stage II (with substantial LVSI) or stage III no-specific molecular profile (NSMP) endometrial cancer are randomised between standard chemoradiation and external beam radiotherapy followed by oral progestin for two years.

The POLEmut-BLUE trial (NCT05640999) is an international, multicenter, single arm, phase II trial wherein safety of de-escalation of adjuvant therapy in POLE-mutated endometrial cancer is investigated.

The overarching RAINBO research project will combine the data and tumor material of the four RAINBO clinical trials to perform translational research and compare molecular profile-based adjuvant therapy to standard adjuvant therapy in terms of effectiveness, toxicity, quality of life and cost utility.

03

Conditions studied

  • Endometrial Cancer

Keywords

  • Endometrial Cancer
  • Molecular risk factors
  • Durvalumab
  • Chemotherapy
  • Radiotherapy
  • MMRd
04

Who can participate

The criteria were revised on the registry on Oct 8, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Participants of the four RAINBO trials should be eligible according to the inclusion and exclusion criteria of both the overarching RAINBO trials program and the clinical trial that they are assigned to based on the molecular profile.

Inclusion Criteria of the overarching RAINBO program:

  • confirmed diagnosis of endometrial cancer (EC) of the following histotypes: endometrioid endometrial carcinoma, serous endometrial carcinoma, uterine clear cell carcinoma, dedifferentiated and undifferentiated endometrial carcinoma, uterine carcinosarcoma and mixed endometrial carcinomas of the aforementioned histotypes.
  • Full molecular classification performed following the diagnostic algorithm described in WHO 2020 (5th Edition, IARC, Lyon, 2020)
  • TLH-BSO or TAH-BSO with or without lymphadenectomy or sentinel node , without macroscopic residual disease after surgery
  • No distant as determined by pre-surgical or post-surgical imaging (CT/MRI scan of chest, abdomen and pelvis or PET-CT scan)
  • Age ≥ 18 years
  • Expected start of treatment (if applicable) within 10 weeks after surgery
  • Patients must be accessible for treatment and follow-up
  • Written for participation in one of the RAINBO trials, permission for the contribution of a tissue block for translation research and permission for the use and sharing of data for the overarching research project according to the local Ethics Committee requirements.

Exclusion Criteria overarching RAINBO program:

  • History of another primary , except for non-melanoma skin cancer, in the past 5 years
  • Prior pelvic radiation

The MMRd-GREEN trial

Inclusion criteria:

  • Written informed consent
  • WHO Performance score 0-1
  • Histologically confirmed FIGO 2009 stage IB/II with LVSI, stage III, or stage IV with limited pelvic peritoneal involvement (FIGO 2023 stage IB with LVSI, stage II with myometrial or cervical stroma involvement and LVSI, or stage III disease)
  • Molecular classification: MMRd EC*
  • No prior pelvic radiotherapy
  • Body weight > 30 kg
  • Adequate systemic organ function:

    • (> 40 cc/min): Measured creatinine clearance (CL) >40 mL/min or Calculated creatinine CL>40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance.
    • Adequate bone marrow function : >9.0 g/dl, (ANC) ≥1.0 x 109/l, count ≥75 x 109/l.
    • Adequate liver function: ≤1.5 x institutional (ULN). \<\<This will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician.>>
    • (SGPT) and/or AST (SGOT) ≤2.5 x ULN

Exclusion criteria:

  • Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of medicinal product (IMP).
  • History of allogenic organ transplantation.
  • Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.
  • Any previous treatment with a PD(L)1 inhibitor, including durvalumab.
  • Receipt of within 30 days prior to the first dose of durvalumab. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 30 days after the last dose of IMP.
  • Current or prior use of medication within 14 days before the first dose of durvalumab with the exceptions of :

    • Intranasal, inhaled, topical , or local steroid injections (e.g., intra articular injection).
    • Systemic corticosteroids at physiologic doses not to exceed \<\<10 mg/day>> of prednisone or its equivalent.
    • Steroids as premedication for reactions (e.g., CT scan premedication).
  • History of active primary immunodeficiency
  • Active or prior documented or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome. The following are exceptions to this criterion:

    • Patients with vitiligo or alopecia
    • Patients with hypothyroidism (e.g., following Hashimoto syndrome)stable on hormone replacement
    • Any chronic skin condition that does not require systemic therapy
    • Patients without active disease in the last 5 years may be included but only after consultation with the study physician.
  • Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), (known positive HBV surface antigen (HBsAg) result), , or human immuno-deficiency virus (positive 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
  • Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
316 participants (estimated)

Study arms

  • Experimental
    MMRd-GREEN trial: experimental

    Adjuvant radiotherapy combined with and followed by durvalumab, 1500 mg intravenous once every 4 weeks for in total 1 year (13 cycles)

    Radiation: Pelvic external beam radiotherapy · Drug: Durvalumab · Radiation: Vaginal brachytherapy

  • Active comparator
    MMRd-GREEN trial: control

    Adjuvant pelvic external beam radiotherapy +/- chemotherapy

    Radiation: Pelvic external beam radiotherapy · Drug: Chemotherapy · Radiation: Vaginal brachytherapy

Interventions

  • RadiationPelvic external beam radiotherapy

    45.0-48.6 Gy; 1.8-2.0 Gy per fraction, 5 fractions a week

    Also known as: EBRT

  • DrugChemotherapy

    Preferably concurrent and adjuvant according to the PORTEC-3 schedule: two cycles of intravenous cisplatin 50mg/m² in the first and fourth week of the pelvic external beam radiotherapy followed by four cycles of intravenous carboplatin AUC 5 and paclitaxel 175 mg/m² at 21-day intervals.

    Also known as: Cisplatin, Carboplatin, Paclitaxel

  • 1500 mg intravenous once every 4 weeks for in total 1 year (13 cycles) starting within the first week of radiotherapy,

    Also known as: Imfinzi

  • RadiationVaginal brachytherapy

    Vaginal brachytherapy is to be considered in patients with documented cervical stromal involvement and/or substantial LVSI. Brachytherapy is given with a vaginal cylinder or vaginal ovoids or ring applicator, according to the center's standard technique. When using a cylinder, the active length will ideally be 2-3 cm, with the reference isodose covering the proximal 2.5-3 cm of the vagina. High-dose-rate (HDR) and pulse-dose-rate (PDR) schedules are permitted, which deliver an EQD2 equivalent dose of 10-14 Gy at 5 mm from the vaginal mucosa (to obtain a cumulative EDQ2 of 60 Gy at 5 mm).

06

What researchers measure

Primary outcomes

  1. Recurrence-free survival

    RFS is defined as time from randomization until date of any recurrence (local or distant) or date of death due to any cause.

    Time frame: 3 years

Secondary outcomes

  1. Efficacy endpoints

    * Investigator assessed median and 5-year RFS * Vaginal RFS, pelvic RFS, distant metastasis free-survival (median, 3-year, 5-year) * Disease-specific survival (median, 3-year, 5-year) * Overall Survival (OS) (median, 3 year, 5 year): will be determined from the date of randomization to the date of death from any cause. Subjects who have not died at the time of data freeze for the final analysis will be censored at the date the patient was last known to be alive.

    Time frame: 5 years

  2. Quality of Life Endpoints

    Quality of life analysis using the EORTC QLQC30 and QLQEN24.

    Time frame: 5 years

  3. Safety and tolerability endpoints.

    Safety and tolerability endpoints will consist of the evaluation of side-effects according to the NCI-CTCAE version 5, AEs, withdrawals due to AEs, dose interruptions.

    Time frame: 3 years, 5 years

  4. Biomarker

    PD-L1 expression assessment using the SP263 immunohistochemistry assay (thresholds: ≥1% and ≥5%)

    Time frame: Baseline

  5. Exploratory translational research

    Exploratory translational research: • MMRd-GREEN specific: \- Evaluation of antigen presentation status (e.g. JAK1/2 and B2M mutational status)

    Time frame: 3 years, 5 years

07

Study locations

60 of 60 sites recruiting
08

References and documents

Publications

  • IMPLEMENTATION OF COLLABORATIVE TRANSLATIONAL RESEARCH (TRANSPORTEC) FINDINGS IN AN INTERNATIONAL ENDOMETRIAL CANCER CLINICAL TRIALS PROGRAM (RAINBO). T Bosse, M Powell, E Crosbie, A Leary, J Kroep, K Han, J Mcalpine, N Horeweg, S De Boer, M De Bruyn, R Nout, V Smit, HW Nijman, N Singh, H Mackay, R Edmondson, L Mileshkin, D Church, H Kitchener, CL Creutzberg. Int J Gynecol Cancer 2021;31(Suppl 3):A1-A395. DOI: 10.1136/ijgc-2021-ESGO.171
  • RAINBO Research Consortium. Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program. Int J Gynecol Cancer. 2023 Jan 3;33(1):109-117. doi: 10.1136/ijgc-2022-004039. PubMed 36600534 ↗
  • Secord AA, Powell MA, McAlpine J. Molecular Characterization and Clinical Implications of Endometrial Cancer. Obstet Gynecol. 2025 Nov 1;146(5):660-671. doi: 10.1097/AOG.0000000000006080. Epub 2025 Sep 18. PubMed 40966692 ↗

Individual participant data

Plan to share: Yes — Following the planned translational work in the RAINBO programme and publications, the translational research (TR) committee will open up the sample collection to external researchers. Access will be granted following completion of a research proposal form and approval by the TR committee chaired by Dr. Tjalling Bosse. All external researchers will be expected to demonstrate funding for their project and ethics approval. Data will be made available as required through data sharing agreements. The following will be reviewed when considering applications for data sharing and sample access: data and sample use is in-keeping with patient consent, the proposed project has scientific value, with defined objectives and study plan, trial data are appropriate for the intended purpose, acknowledgement of the RAINBO Programme in all publications that arise from the data sharing, compliance with legal and regulatory requirements as applicable and patient confidentiality maintained at all times.

Supporting information: Study protocol

Time frame: After the publication of the trial's final results.

Access criteria: Public

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Jan 2030, 97 months after the start.

Of 45 phase 3 interventional studies under Endometrial Neoplasms, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 126. This study's planned 97 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2022
First posted
Feb 24, 2022
StartActual
Nov 11, 2021
Primary completionEst.
Jan 1, 2030
CompletionEst.
Jan 1, 2031
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
53 sites added, 7 sites removed — first sites in Belgium, Czechia, Germany and Italy; no longer in United Kingdom
Show 53 added (15 Canada, 11 Germany, 10 France, 6 Belgium, 6 Netherlands, 4 Czechia, 1 Italy)
  • Antwerp University Hospital · Antwerp, Belgium
  • Clinique Universitaire Saint-Luc · Brussels, Belgium
  • GHDC · Charleroi, Belgium
  • CHU Helora · Mons, Belgium
  • CHU UCL Namur · Namur, Belgium
  • AZ Damiaan · Ostend, Belgium
  • Juravinski Cancer Center · Hamilton, Canada
  • BCCA Kelowna · Kelowna, Canada
  • Kingston Health Sciences Centre · Kingston, Canada
  • London Regional Cancer Centre · London, Canada
  • Centre Hospitalier de Universite de Montreal · Montreal, Canada
  • Jewish General Hospital · Montreal, Canada
  • Maisonneuve-Rosemont Hospital · Montreal, Canada
  • Allan Blair Cancer Centre · Regina, Canada
  • Saint John Regional Center · Saint John, Canada
  • Saskatoon Cancer Centre · Saskatoon, Canada
  • Centre hospitalier universitaire de Sherbrooke · Sherbrooke, Canada
  • Princess Margaret Cancer Centre · Toronto, Canada
  • Sunnybrook Health Science Centre · Toronto, Canada
  • BC Cancer Vancouver · Vancouver, Canada
  • BCCA Victoria · Victoria, Canada
  • Fakultní nemocnice Hradec Králové · Hradec Králové, Czechia
  • FN Bulovka · Prague, Czechia
  • FN Motol · Prague, Czechia
  • Všeobecná fakultní nemocnice v Praze · Prague, Czechia
  • CHU Jean Minjoz · Besançon, France
  • Institut Bergonie · Bordeaux, France
  • Institut Leon Berard · Lyon, France
  • Institut Paoli Calmattes-Marseille · Marseille, France
  • Institut du cancer de Montpellier · Montpellier, France
  • …and 23 more on the registry record
Show 7 removed
  • The POLEmut-BLUE trial: Princess Margaret Cancer Centre, University of Toronto · Toronto, Canada
  • The POLEmut-BLUE trial: University of British Columbia · Vancouver, Canada
  • The p53abn-RED trial: Institute Gustave Roussy · Villejuif, France
  • The MMRd-GREEN trial: Leiden University Medical Center · Leiden, Netherlands
  • Haags Medisch Centrum · The Hague, Netherlands
  • The NSMP-ORANGE trial: Barts Health NHS Trust · London, United Kingdom
  • The NSMP-ORANGE trial: Manchester Academic Health Science Centre, St Mary's Hospita · Manchester, United Kingdom
Oct 8, 2026
Enrollment
1615→316
Oct 8, 2026
Eligibility
3 criteria edited, 6 added, 59 removed
What changed in the criteria
  • EditedHysterectomy and bilateral salpingoTLH-BSO or TAH-oophorectomyBSO with or without lymphadenectomy or sentinel node biopsy, without macroscopic residual disease after surgery
  • EditedNo distant metastases as determined by pre-surgical or post-surgical imaging (CT/MRI scan of chest, abdomen and pelvis or whole-body PET-CT scan)
  • RemovedWHO performance status 0, 1 or 2
  • AddedAge ≥ 18 years
  • RemovedThe p53abn-RED trial
  • RemovedInclusion criteria:
  • RemovedMismatch repair deficient EC
  • RemovedHistologically confirmed (FIGO 2009) stage IB/II EC with myometrial or cervical stroma involvement and lympovascular space invasion (LVSI) OR Stage III EC OR Stage IVA with limited pelvic peritoneal involvement
  • RemovedWHO Performance score 0-1
  • RemovedBody weight > 30 kg
  • RemovedAdequate systemic organ function:
  • RemovedCreatinine clearance (> 40 cc/min): Measured creatinine clearance (CL) >40 mL/min or Calculated creatinine CL>40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance.
  • RemovedAdequate bone marrow function : hemoglobin >9.0 g/dl, Absolute neutrophil count (ANC) ≥1.0 x 109/l, platelet count ≥75 x 109/l.
  • Removedp53 abnormal EC
  • RemovedHistologically confirmed stage I (with invasion) II or III EC
  • AddedWritten informed consent
  • AddedHistologically confirmed FIGO 2009 stage IB/II with LVSI, stage III, or stage IV with limited pelvic peritoneal involvement (FIGO 2023 stage IB with LVSI, stage II with myometrial or cervical stroma involvement and LVSI, or stage III disease)
  • AddedMolecular classification: MMRd EC*
  • AddedNo prior pelvic radiotherapy
  • RemovedAdequate liver function: bilirubin ≤1.5 x institutional upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician, AND ALT (SGPT) and/or AST (SGOT) ≤2.5 x ULN
  • EditedAdequate liver function: bilirubinBilirubin ≤1.5 x institutional upper limit of normal (ULN). <<This will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician.>> AND ALT (SGPT) and/or AST (SGOT) ≤2.5 x ULN
  • RemovedExclusion criteria:
  • RemovedPathogenic POLE mutation(s)
  • AddedALT (SGPT) and/or AST (SGOT) ≤2.5 x ULN
  • RemovedPathogenic POLE mutation(s)
  • RemovedMismatch repair deficiency
  • RemovedMajor surgical procedure (as defined by the investigator) within 28 days prior to the first dose of the IP
  • RemovedHistory of allogenic organ transplantation
  • RemovedUncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.
  • RemovedAny previous treatment with a PARP inhibitor, including olaparib
  • RemovedHistory of active primary immunodeficiency
  • RemovedHistory or evidence of hemorrhagic disorders within 6 months prior to randomization
  • RemovedPatients with myelodysplastic syndrome/acute myeloid leukemia history or with features suggestive of MDS/AML
  • RemovedPrevious allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT)
  • RemovedActive infection, including: tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immuno-deficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
  • RemovedConcomitant use of known strong CYP3A inhibitors (eg. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting olaparib is 2 weeks.
  • RemovedConcomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate CYP3A inducers (eg. bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.
  • RemovedPatients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
  • RemovedMedical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent.
  • RemovedThe NSMP-ORANGE trial

…and 28 more changes, on the record history on ClinicalTrials.gov ↗

Oct 8, 2026
Interventions
Removed Drug: Olaparib·Drug: Medroxyprogesterone Acetate·Drug: Megestrol Acetate·Observation. Arms removed: p53abn-RED trial: experimental·p53abn-RED trial: control·NSMP-ORANGE trial: experimental·NSMP-ORANGE trial: control·POLEmut-BLUE trial: main cohort·and 1 more
All 6

p53abn-RED trial: experimental · p53abn-RED trial: control · NSMP-ORANGE trial: experimental · NSMP-ORANGE trial: control · POLEmut-BLUE trial: main cohort · POLEmut-BLUE trial: exploratory cohort

Oct 8, 2026
Primary outcomes
1 added, 4 removed
What changed in the outcomes
  • AddedRecurrence-free survivalTime frame: 3 years
  • Removedp53abn-RED trialTime frame: 3 years
  • RemovedMMRd-GREEN trialTime frame: 3 years
  • RemovedNSMP-ORANGE trialTime frame: 3 years
  • RemovedPOLEmut-BLUE trialTime frame: 3 years
Oct 8, 2026
Secondary outcomes
5 added, 8 removed
What changed in the outcomes
  • AddedEfficacy endpointsTime frame: 5 years
  • AddedQuality of Life EndpointsTime frame: 5 years
  • AddedSafety and tolerability endpoints.Time frame: 3 years, 5 years
  • AddedBiomarkerTime frame: Baseline
  • AddedExploratory translational researchTime frame: 3 years, 5 years
  • RemovedRecurrence-free survivalTime frame: 5 years
  • RemovedPelvic recurrence-free survivalTime frame: 5 years
  • RemovedVaginal recurrence-free survivalTime frame: 3 years, 5 years
  • RemovedEndometrial cancer-specific survivalTime frame: 3 years, 5 years
  • RemovedOverall survivalTime frame: 3 years, 5 years
  • RemovedTreatment-related toxicity - according to CTCAE v5.0Time frame: 3 years, 5 years
  • RemovedHealth-related quality of life - Assessed using the EORTC QLQ-C30 questionnaireTime frame: 3 years, 5 years
  • RemovedHealth-related quality of life - Assessed using the EORTC QLQ-EN24 questionnaireTime frame: 3 years, 5 years
Oct 8, 2026
Contact
Study contact changed: c•••@lumc.nl · •••5539→C•••@lumc.nl · •••3500; n•••@lumc.nl · •••5539→C•••@lumc.nl. See the current contact
Oct 8, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Amsterdam University Medical Center · Amsterdam, NetherlandsContact j•••@amsterdamumc.nl→j•••@amsterdamumc.nl
  • Catharina Ziekenhuis · Eindhoven, NetherlandsContact a•••@catharinaziekenhuis.nl→a•••@catharinaziekenhuis.nl
  • Medisch Spectrum Twente · Enschede, NetherlandsContact a•••@mst.nl→a•••@mst.nl
Oct 8, 2026
Sponsor
Collaborators added: BGOG: Belgian Gynaelogical Onology Group, Belgium·Fondazione Policlinico Universitario Agostino Gemelli IRCCS·Institute Gustave Roussy Paris·Central & Eastern European Gynecologic Oncology Group (CEEGOG)·Canadian Cancer Trials Group (CCTG); collaborators removed: Institute Gustave Roussy (sponsor p53abn-RED trial)·Leiden University Medical center (sponsor MMRd-GREEN trial)·University College London (sponsor NSMP-ORANGE trial)·Canadian Clinical Trials Group (sponsor POLEmut-BLUE trial)·Comprehensive Cancer Centre The Netherlands
Oct 8, 2026
Design
Removed Phase 2
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    53 sites added, 7 sites removed — first sites in Belgium, Czechia, Germany and Italy; no longer in United Kingdom
    Show 53 added (15 Canada, 11 Germany, 10 France, 6 Belgium, 6 Netherlands, 4 Czechia, 1 Italy)
    • Antwerp University Hospital · Antwerp, Belgium
    • Clinique Universitaire Saint-Luc · Brussels, Belgium
    • GHDC · Charleroi, Belgium
    • CHU Helora · Mons, Belgium
    • CHU UCL Namur · Namur, Belgium
    • AZ Damiaan · Ostend, Belgium
    • Juravinski Cancer Center · Hamilton, Canada
    • BCCA Kelowna · Kelowna, Canada
    • Kingston Health Sciences Centre · Kingston, Canada
    • London Regional Cancer Centre · London, Canada
    • Centre Hospitalier de Universite de Montreal · Montreal, Canada
    • Jewish General Hospital · Montreal, Canada
    • Maisonneuve-Rosemont Hospital · Montreal, Canada
    • Allan Blair Cancer Centre · Regina, Canada
    • Saint John Regional Center · Saint John, Canada
    • Saskatoon Cancer Centre · Saskatoon, Canada
    • Centre hospitalier universitaire de Sherbrooke · Sherbrooke, Canada
    • Princess Margaret Cancer Centre · Toronto, Canada
    • Sunnybrook Health Science Centre · Toronto, Canada
    • BC Cancer Vancouver · Vancouver, Canada
    • BCCA Victoria · Victoria, Canada
    • Fakultní nemocnice Hradec Králové · Hradec Králové, Czechia
    • FN Bulovka · Prague, Czechia
    • FN Motol · Prague, Czechia
    • Všeobecná fakultní nemocnice v Praze · Prague, Czechia
    • CHU Jean Minjoz · Besançon, France
    • Institut Bergonie · Bordeaux, France
    • Institut Leon Berard · Lyon, France
    • Institut Paoli Calmattes-Marseille · Marseille, France
    • Institut du cancer de Montpellier · Montpellier, France
    • …and 23 more on the registry record
    Show 7 removed
    • The POLEmut-BLUE trial: Princess Margaret Cancer Centre, University of Toronto · Toronto, Canada
    • The POLEmut-BLUE trial: University of British Columbia · Vancouver, Canada
    • The p53abn-RED trial: Institute Gustave Roussy · Villejuif, France
    • The MMRd-GREEN trial: Leiden University Medical Center · Leiden, Netherlands
    • Haags Medisch Centrum · The Hague, Netherlands
    • The NSMP-ORANGE trial: Barts Health NHS Trust · London, United Kingdom
    • The NSMP-ORANGE trial: Manchester Academic Health Science Centre, St Mary's Hospita · Manchester, United Kingdom
    Enrollment 1615→316
    Eligibility 3 criteria edited, 6 added, 59 removed
    What changed in the criteria
    • EditedHysterectomy and bilateral salpingoTLH-BSO or TAH-oophorectomyBSO with or without lymphadenectomy or sentinel node biopsy, without macroscopic residual disease after surgery
    • EditedNo distant metastases as determined by pre-surgical or post-surgical imaging (CT/MRI scan of chest, abdomen and pelvis or whole-body PET-CT scan)
    • RemovedWHO performance status 0, 1 or 2
    • AddedAge ≥ 18 years
    • RemovedThe p53abn-RED trial
    • RemovedInclusion criteria:
    • RemovedMismatch repair deficient EC
    • RemovedHistologically confirmed (FIGO 2009) stage IB/II EC with myometrial or cervical stroma involvement and lympovascular space invasion (LVSI) OR Stage III EC OR Stage IVA with limited pelvic peritoneal involvement
    • RemovedWHO Performance score 0-1
    • RemovedBody weight > 30 kg
    • RemovedAdequate systemic organ function:
    • RemovedCreatinine clearance (> 40 cc/min): Measured creatinine clearance (CL) >40 mL/min or Calculated creatinine CL>40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance.
    • RemovedAdequate bone marrow function : hemoglobin >9.0 g/dl, Absolute neutrophil count (ANC) ≥1.0 x 109/l, platelet count ≥75 x 109/l.
    • Removedp53 abnormal EC
    • RemovedHistologically confirmed stage I (with invasion) II or III EC
    • AddedWritten informed consent
    • AddedHistologically confirmed FIGO 2009 stage IB/II with LVSI, stage III, or stage IV with limited pelvic peritoneal involvement (FIGO 2023 stage IB with LVSI, stage II with myometrial or cervical stroma involvement and LVSI, or stage III disease)
    • AddedMolecular classification: MMRd EC*
    • AddedNo prior pelvic radiotherapy
    • RemovedAdequate liver function: bilirubin ≤1.5 x institutional upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician, AND ALT (SGPT) and/or AST (SGOT) ≤2.5 x ULN
    • EditedAdequate liver function: bilirubinBilirubin ≤1.5 x institutional upper limit of normal (ULN). <<This will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician.>> AND ALT (SGPT) and/or AST (SGOT) ≤2.5 x ULN
    • RemovedExclusion criteria:
    • RemovedPathogenic POLE mutation(s)
    • AddedALT (SGPT) and/or AST (SGOT) ≤2.5 x ULN
    • RemovedPathogenic POLE mutation(s)
    • RemovedMismatch repair deficiency
    • RemovedMajor surgical procedure (as defined by the investigator) within 28 days prior to the first dose of the IP
    • RemovedHistory of allogenic organ transplantation
    • RemovedUncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.
    • RemovedAny previous treatment with a PARP inhibitor, including olaparib
    • RemovedHistory of active primary immunodeficiency
    • RemovedHistory or evidence of hemorrhagic disorders within 6 months prior to randomization
    • RemovedPatients with myelodysplastic syndrome/acute myeloid leukemia history or with features suggestive of MDS/AML
    • RemovedPrevious allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT)
    • RemovedActive infection, including: tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immuno-deficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
    • RemovedConcomitant use of known strong CYP3A inhibitors (eg. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting olaparib is 2 weeks.
    • RemovedConcomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate CYP3A inducers (eg. bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.
    • RemovedPatients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
    • RemovedMedical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent.
    • RemovedThe NSMP-ORANGE trial

    …and 28 more changes, on the record history on ClinicalTrials.gov ↗

    Primary outcomes 1 added, 4 removed
    What changed in the outcomes
    • AddedRecurrence-free survivalTime frame: 3 years
    • Removedp53abn-RED trialTime frame: 3 years
    • RemovedMMRd-GREEN trialTime frame: 3 years
    • RemovedNSMP-ORANGE trialTime frame: 3 years
    • RemovedPOLEmut-BLUE trialTime frame: 3 years
    Secondary outcomes 5 added, 8 removed
    What changed in the outcomes
    • AddedEfficacy endpointsTime frame: 5 years
    • AddedQuality of Life EndpointsTime frame: 5 years
    • AddedSafety and tolerability endpoints.Time frame: 3 years, 5 years
    • AddedBiomarkerTime frame: Baseline
    • AddedExploratory translational researchTime frame: 3 years, 5 years
    • RemovedRecurrence-free survivalTime frame: 5 years
    • RemovedPelvic recurrence-free survivalTime frame: 5 years
    • RemovedVaginal recurrence-free survivalTime frame: 3 years, 5 years
    • RemovedEndometrial cancer-specific survivalTime frame: 3 years, 5 years
    • RemovedOverall survivalTime frame: 3 years, 5 years
    • RemovedTreatment-related toxicity - according to CTCAE v5.0Time frame: 3 years, 5 years
    • RemovedHealth-related quality of life - Assessed using the EORTC QLQ-C30 questionnaireTime frame: 3 years, 5 years
    • RemovedHealth-related quality of life - Assessed using the EORTC QLQ-EN24 questionnaireTime frame: 3 years, 5 years
    Interventions Removed Drug: Olaparib·Drug: Medroxyprogesterone Acetate·Drug: Megestrol Acetate·Observation. Arms removed: p53abn-RED trial: experimental·p53abn-RED trial: control·NSMP-ORANGE trial: experimental·NSMP-ORANGE trial: control·POLEmut-BLUE trial: main cohort·and 1 more
    All 6

    p53abn-RED trial: experimental · p53abn-RED trial: control · NSMP-ORANGE trial: experimental · NSMP-ORANGE trial: control · POLEmut-BLUE trial: main cohort · POLEmut-BLUE trial: exploratory cohort

    Sponsor Collaborators added: BGOG: Belgian Gynaelogical Onology Group, Belgium·Fondazione Policlinico Universitario Agostino Gemelli IRCCS·Institute Gustave Roussy Paris·Central & Eastern European Gynecologic Oncology Group (CEEGOG)·Canadian Cancer Trials Group (CCTG); collaborators removed: Institute Gustave Roussy (sponsor p53abn-RED trial)·Leiden University Medical center (sponsor MMRd-GREEN trial)·University College London (sponsor NSMP-ORANGE trial)·Canadian Clinical Trials Group (sponsor POLEmut-BLUE trial)·Comprehensive Cancer Centre The Netherlands
    Design Removed Phase 2
    Contact Study contact changed: c•••@lumc.nl · •••5539→C•••@lumc.nl · •••3500; n•••@lumc.nl · •••5539→C•••@lumc.nl. See the current contact
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Amsterdam University Medical Center · Amsterdam, NetherlandsContact j•••@amsterdamumc.nl→j•••@amsterdamumc.nl
    • Catharina Ziekenhuis · Eindhoven, NetherlandsContact a•••@catharinaziekenhuis.nl→a•••@catharinaziekenhuis.nl
    • Medisch Spectrum Twente · Enschede, NetherlandsContact a•••@mst.nl→a•••@mst.nl
    + 6 other changes: index terms, identifiers, verification date, description, conditions and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05255653
Collaborators
Dutch Gynaecological Oncology Group, Cancer Research UK & UCL Cancer Trials Centre, Dutch Cancer Society, AstraZeneca, National Cancer Institute, France, Canadian Institutes of Health Research (CIHR), BGOG: Belgian Gynaelogical Onology Group, Belgium, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Institute Gustave Roussy Paris, Central & Eastern European Gynecologic Oncology Group (CEEGOG), Canadian Cancer Trials Group (CCTG)
Responsible party
J.R. Kroep (prof, Leiden University Medical Center) — Principal investigator
First posted
Feb 24, 2022
Start date
Nov 11, 2021
Primary completion
Jan 1, 2030 (estimated)
Completion
Jan 1, 2031 (estimated)
Last update
Oct 8, 2026

Study contacts

Elma Meershoek- Klein Kranenbarg
Contact
ClinicalResearchCenter@lumc.nl
0031 71 526 3500
Annet Roodvoets
Contact
ClinicalResearchCenter@lumc.nl
Judith R Kroep, MD PhD
principal investigator · Medical Oncology, Leiden University Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion